Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic adult adipose-derived mesenchymal stem cells
- Development stage
- Phase 2
- Lead developer
- National Yang Ming Chiao Tung University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs) harvested from healthy donors. Developed by researchers at National Yang Ming Chiao Tung University (formerly National Yang-Ming University) in Taiwan, the therapy is being evaluated for the treatment of neurodegenerative cerebellar disorders, specifically spinocerebellar ataxia type 3 (SCA3) and the cerebellar type of multiple system atrophy (MSA-C). Administered intravenously, these stem cells are hypothesized to exert neuroprotective effects by migrating to damaged tissues and secreting trophic factors that support cerebellar Purkinje cells and modulate the inflammatory environment associated with neurodegeneration. Results from a Phase I/IIa open-label study involving six patients with SCA3 and one with MSA-C indicated that the infusion was well-tolerated and potentially stabilized or retarded disease progression compared to the natural history of the diseases.
- Other names
- allogeneic adult adipose-derived mesenchymal stem cells-National Yang Ming Chiao Tung University-spinocerebellar ataxia type 3-multiple system atrophy (cerebellar type)AD-MSCsallogeneic adipose tissue-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic adult adipose-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic adult adipose-derived mesenchymal stem cells.